Denis Patrick

Dr. Patrick is Vice President and Managing Partner of Pfizer Ventures where investments are made in early stage companies in the areas of Oncology, Immunology, Internal Medicine, Neuroscience, Vaccines and Rare Diseases. Recent company investments include: Artios, Strata, Kymera, Theracon, Janana, Arrakis, Magnolia and System1. Dr. Patrick is a member of the Board of Directors for several portfolio companies including Mission Therapeutics, Metabomed, eFFECTOR Therapeutics, NextCure, Encycle Therapeutics, and AnTolRx.
Dr. Patrick is also Head of Partnering Innovation in the Emerging Science & Innovation department at Pfizer Inc. This work involves managing public/private partnerships and additionally creating novel partnering models.
Previously, Dr. Patrick served as Head of Oncology Licensing for Worldwide R&D at Pfizer from 2010 to 2018. In this capacity some of his recent executed agreements included acquisitions of Medivation and BIND Therapeutics, and research licenses with CytomX, Stemcentrx, iTeos, BioAtla, Western Oncolytics and Arvinas.
Dr. Patrick received his Ph.D. in Biochemistry from the University of Pennsylvania and has worked for several large Pharma oncology organizations, including Merck, DuPont Pharma, GlaxoSmithKline and Pfizer. While at GlaxoSmithKline, Dr. Patrick lead several drug discovery teams and contributed significantly to several oncology drug discovery efforts that resulted in FDA approval and marketing of three therapeutic oncology agents including Arranon, TafinlarĀ® and MekinistĀ®.